Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

SciNeuro Signs Up Secarna to Discover Antisense Oligonucleotide Therapies for Neurology Targets

publication date: Mar 30, 2023

SciNeuro Pharmaceuticals, a Shanghai CNS company, signed a research agreement with Munich’s Secarna Pharma to discover next-gen antisense oligonucleotide (ASO) therapies for undruggable neurological targets. Secarna will use its nucleic acid discovery platform, LNAplusTM, to generate and profile antisense oligonucleotide candidates against targets selected by SciNeuro. SciNeuro has an option for exclusive worldwide rights to the candidates. Founded in 2020, SciNeuro was launched with $100 million in initial funding. The company is led by Min Li, PhD, a Venture Partner at Lilly Asia Ventures, who was head of GSK’s Shanghai R&D center until it was shut down in 2017. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital